Voyager Therapeutics (VYGR) Rating Increased to Hold at Zacks Investment Research
Voyager Therapeutics (NASDAQ:VYGR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Saturday.
According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
A number of other equities research analysts have also recently weighed in on VYGR. Chardan Capital restated a “hold” rating on shares of Voyager Therapeutics in a report on Sunday, September 10th. ValuEngine upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Raymond James Financial initiated coverage on Voyager Therapeutics in a report on Thursday, October 12th. They issued an “outperform” rating and a $35.00 price target on the stock. Stifel Nicolaus restated a “buy” rating and issued a $31.00 price target (up previously from $20.00) on shares of Voyager Therapeutics in a report on Monday, October 23rd. Finally, Canaccord Genuity initiated coverage on Voyager Therapeutics in a report on Friday, October 27th. They issued a “buy” rating and a $35.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $26.90.
In other Voyager Therapeutics news, insider Bernard Ravina sold 10,980 shares of the stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $20.33, for a total transaction of $223,223.40. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders have sold 21,960 shares of company stock worth $370,850. 8.00% of the stock is owned by insiders.
Large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. grew its holdings in Voyager Therapeutics by 57.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock valued at $106,000 after buying an additional 4,343 shares during the last quarter. Strs Ohio grew its holdings in Voyager Therapeutics by 531.6% during the 2nd quarter. Strs Ohio now owns 12,000 shares of the company’s stock valued at $131,000 after buying an additional 10,100 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Voyager Therapeutics during the 3rd quarter valued at $270,000. Aberdeen Asset Management PLC UK acquired a new stake in Voyager Therapeutics during the 4th quarter valued at $177,000. Finally, Hershey Trust Co. grew its holdings in Voyager Therapeutics by 163.0% during the 2nd quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock valued at $129,000 after buying an additional 8,921 shares during the last quarter. Hedge funds and other institutional investors own 35.97% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Voyager Therapeutics (VYGR) Rating Increased to Hold at Zacks Investment Research” was published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/06/voyager-therapeutics-vygr-rating-increased-to-hold-at-zacks-investment-research.html.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.